Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cannabis Enforcement topic
No spam. Unsubscribe anytime.
Heated public testimony as Senate panel considers bill to criminalize sale of cannabis by unlicensed sellers
Summary
The Senate Judiciary Committee held an extended hearing on S4154, a bill establishing crimes for selling or purchasing cannabis from unlicensed businesses. Industry, municipal leaders and patient advocates testified in opposition and support, framing the measure as either necessary enforcement or a rollback that could criminalize vulnerable people.
The Senate Judiciary Committee on May 29 devoted much of its afternoon to S4154, a measure sponsored by the Senate President that would make it a crime to sell or purchase cannabis from unlicensed businesses. The bill prompted lengthy debate and numerous public witnesses who articulated sharply divergent views on how to curb unregulated storefronts while protecting patients and social-equity goals.
Supporters — including licensed operators, municipal officials and unions — said local governments and legitimate businesses are losing customers and revenue to unlicensed sellers in convenience stores and smoke shops. Bill Caruso, legislative counsel to municipal leaders, told the committee local officials and police chiefs want clear guidance from the Attorney General and regulators on enforcement and testing protocols. A Trenton official said legal operators in his city are again at risk of closure because illicit storefronts are undercutting the market and depriving municipalities of tax revenue.
Opponents — including patient advocates, legacy growers and testing-laboratory representatives — warned the bill could recriminalize patients and low-income people who cannot access dispensaries, and urged alternatives. Michael Brennan of the Coalition for Medical Marijuana said the enacted regulatory system is overpriced and underperforming for patients and described S4154 as a “direct attack” that could return New Jersey to a punitive approach. Licensed dispensary owners stressed that fixing product-safety standards, testing and access would be more effective than adding criminal penalties. Several witnesses recommended strengthening retail licensing and enforcement mechanisms (licensing of retailers, clearer hemp definitions, retail oversight) rather than criminalizing consumers.
Technical details drove much of the exchange. Laboratory and hemp-industry witnesses identified gaps in the definition and enforcement distinction between hemp-derived products and regulated cannabis, and urged either clearer hemp legislation or a licensing system under the Department of Agriculture for hemp retail. Multiple witnesses urged coordinated action among the Cannabis Regulatory Commission, the Department of Agriculture, county prosecutors and the Attorney General to ensure consistent testing, confiscation procedures and penalties that target bad actors, not patients.
Committee members acknowledged the urgency of protecting children and the regulated market but also expressed caution about unintended consequences. Several senators asked the Attorney General and county prosecutors to produce enforcement statistics and clarify the scope of their authority. The chair indicated some related hemp legislation had been held for separate consideration and that sponsors intended further work before any final vote.
The committee recorded extensive testimony for the record and did not immediately adopt S4154 on final passage; transcript entries show both strong municipal and industry support for enforcement tools and equally strong opposition from patient and legacy-grower advocates.
